PharmaVitae explores United Therapeutics’ prescription pharmaceutical performance and outlook over 2019–29.
Snapshot Overview – United Therapeutics’ prescription pharmaceutical business is heavily impacted by generic competition. Key themes –  Generic competition is causing a severe impact on United Therapeutics’ pharmaceutical business, with Adcirca and Remodulin impacted in 2019  Recent settlements with Watson and Actavis regarding generic versions of Tyvaso and Orenitram will keep generics at bay until 2026 and 2027  Future growth depends on ralinepag, which United Therapeutics in-licensed from Arena for $1.2bn, with $800m upfront.
Model updates (29 April 2020)
No changes to forecasts.
Model updates (26 February 2020)
Tyvaso forecast adjusted higher due to results from Phase III INCREASE trial in patients with PH-ILD.
Model updates (7 November 2019)
Remodulin forecast adjusted higher due to larger number of patients treated and lower impact from generics in international markets Unituxin forecast adjusted higher due to continued momentum in the US.
Model updates (12 July 2019)
Remodulin sales adjusted lower internationally due to generic entrants Tyvaso sales adjusted higher due to delaying generic entry until 2026 Orenitram sales adjusted higher due to delaying generic entry until 2027 Removed esuberaprost from forecast after failed Phase III BEAT trial Ralinepag forecast added.
Our reports have been used by over 10K customers, including:
Rhinitis Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Rhinitis Global Clinical Trials Review, H2, 2020" provides an overview of Rhinitis Clinical trials scenario.This report provides top line data relating to the clinical trials on Rhinitis. Report includes an overview...
228 pages •
By Asia Market Information & Development Company
• Sep 2020
China’s demand for Pediatric Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, imports & exports, consumer consumption...
The Global Monoclonal Antibody Partnering Terms and Agreements 2014 to 2020 report provides a detailed understanding and analysis of how and why companies enter monoclonal antibody partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors...
Uveal Melanoma Disease - Global Clinical Trials Review, H2, 2020 Summary clinical trial report, “Uveal Melanoma Disease - Global Clinical Trials Review, H2, 2020" provides an overview of Uveal Melanoma Clinical trials scenario.This report provides top line data relating to the clinical trials on...
Global Infectious Diseases Partnering 2014 to 2020 provides the full collection of Infectious Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014. Trends in Infectious Diseases partnering deals Financial deal terms for headline, upfront and royalty by stage of development Infectious...
The Global Diagnostics Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the diagnostic partnering agreements entered into by the worlds leading companies. Comprehensive directory of diagnostic deals since 2014 Diagnostic contract documents Diagnostic...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.